Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
3,636 total articles
Shannon L. Devers, Executive Vice President and Chief Human Resources Officer at Ionis Pharmaceuticals, sold 20,006 shares on March 3, 2026, for about $1.59 million after exercising options to acquire the same number of shares. The company recently secured FDA Priority Review for olezarsen with a target action date of June 30, 2026, and will presen…
Allene M. Diaz, a director at Ionis Pharmaceuticals, sold $4.35 million of company stock on March 3, 2026, and exercised options to acquire an additional 40,321 shares. The transactions occurred under a Rule 10b5-1 plan and follow a period of strong one-year performance for the stock. Separately, Ionis has an FDA decision pending for olezarsen and …
C. Frank Bennett, Executive Vice President and Chief Scientific Officer of Ionis Pharmaceuticals (IONS), sold 85,089 shares on March 3, 2026, generating roughly $6.74 million in proceeds. Bennett also exercised options to acquire 65,089 shares at strike prices of $32.6 and $60.89, costing $3,497,530. After the transactions he directly holds 80,554 …
Warner Bros. Discovery Chief Executive David Zaslav completed a sale of 4,004,149 shares of Series A common stock on March 3, 2026, realizing $113,157,250 at a weighted average price of $28.26. The transaction leaves Zaslav with 7,200,627 directly held shares, while his spouse retains 153 indirect shares. The sale follows a 145% one-year return for…
Jesse Chen, a director at AXT Inc (NASDAQ: AXTI), disposed of 19,947 shares across March 4 and 5, 2026, generating $768,195 in proceeds. The stock has seen dramatic one-year gains, while the company has cut its fourth-quarter revenue guidance and analysts have adjusted ratings and price targets amid market and export-permit constraints.
GeneDx Holdings Corp. (NASDAQ: WGS) Chief Financial Officer Kevin Feeley sold 6,187 Class A shares on March 4, 2026, realizing $486,370. The sale, disclosed on a Form 4 filing, was executed to satisfy tax withholding tied to the vesting and settlement of a performance-based restricted stock unit award. The transactions occur alongside the company’s…
Dennis Howard, Charles Schwab's Chief Technology, Operations & Data Officer, sold 10,108 shares of common stock on March 3, 2026, in two transactions that together totaled about $956,227. The trades were carried out under a Rule 10b5-1 trading plan adopted November 25, 2025. Schwab shares trade near $95.41 and InvestingPro rates the stock as underv…
Alpha Metallurgical Resources Chief Financial Officer Joshua Todd Munsey sold 2,523 shares on March 4, 2026 for $183.24 per share, generating $462,314 in proceeds. The move comes as the stock has weakened and the company posted disappointing fourth-quarter 2025 results, prompting analyst caution and signaling persistent cost and margin pressures in…
Hercules Capital Chief Operating Officer Christian Follmann bought 5,000 shares of HTGC on March 4, 2026, spending $73,400. The purchase brings his direct holding to 150,135 shares. The transaction occurs amid the firm’s preliminary year-end NAV update, a loan amendment with Savara Inc., an analyst downgrade from Piper Sandler, and a critical short…
Ovintiv Inc. director Mayson Howard John sold 5,000 shares on March 3, 2026, realizing $261,950 at $52.39 per share. The transaction occurred while the stock traded close to its 52-week high following a six-month, 30% advance. The company also posted stronger-than-expected fourth-quarter 2025 earnings, while revenue matched forecasts.
Edmund Dunn, Principal Accounting Officer at Monte Rosa Therapeutics, sold 139 shares of common stock on March 4, 2026, in automatic transactions to satisfy tax withholding on vested restricted stock units. The sale, executed at $17.96 per share for a total of $2,496, leaves Dunn with 22,554 shares. The move comes amid rising GLUE share prices, rec…
Lara J. Kroll, SVP and Chief Accounting Officer at Chord Energy Corp (NYSE: CHRD), sold 5,000 shares on March 3, 2026, for roughly $568,300. The transaction occurred at an average price of $113.66 per share, with prices between $113.51 and $113.92. Separately, Chord reported fourth-quarter 2025 results with EPS of $1.28 versus an expected $1.40 and…
Cristen L. Kogl, Chief Legal Officer of Zebra Technologies Corp (NASDAQ: ZBRA), reported a series of transactions in early March including sales, acquisitions and the exercise of stock appreciation rights. The Form 4 filing outlines sales on March 4-5, purchases on March 3 and 5, and the exercise of SARs, leaving Kogl with 23,687 directly held shar…
Steven B. Klinsky, a director of New Mountain Finance Corp (NASDAQ: NMFC), purchased $3,516,053 of common stock across transactions on March 3 and March 4, 2026. The buys occurred at prices between $7.9426 and $8.1671 per share. The transactions increase Klinsky's direct stake to 116,823.91 shares. The trades come as NMFC shares trade near $8.10, c…
Cogent Communications director Sheryl Lynn Kennedy sold 3,300 shares on March 5, 2026, for $75,867. The transaction leaves her with 10,100 shares. The company reported fourth-quarter 2025 results that beat EPS expectations but missed on revenue, prompting several analysts to lower price targets and revise forecasts.
Murray Stahl, President and Co-Portfolio Manager of RENN Fund, Inc. (RCG), bought 1,134 shares on March 4, 2026, at $2.88 per share, spending $3,265 in total. The transactions included both direct and indirect purchases across several affiliated entities. After the transactions Stahl directly holds 152,414 shares of RCG common stock. RCG shares tra…
Gold.com director John Moorhead disposed of 2,000 shares on March 4, 2026, for about $114,103, at a weighted average price of $57.0516. The company also announced a $150 million private placement with TPM, S.A. de C.V., an affiliate of Tether Global Investments Fund, and DA Davidson raised its price target on Gold.com to $53 while maintaining a Buy…
Reed Terrence, Senior Vice President and Chief Human Resources Officer of Comfort Systems USA Inc. (NYSE: FIX), reported two sales totaling $2,537,182 in company common stock in filings with the SEC. The disposals occurred as the stock traded close to its 52-week high and after the company posted stronger-than-expected fourth-quarter 2025 results t…
A Form 4 filing shows Comfort Systems USA Inc. director Darcy Anderson sold 4,500 shares of the company on March 3, 2026, at an average price of $1,369.7418, for proceeds of $6,163,838. The sale occurs while the stock trades close to its 52-week peak and after a quarter of results that outperformed expectations and prompted an analyst price-target …
Horizon Kinetics Asset Management LLC, a roughly 10% owner of Texas Pacific Land Corp (TPL), purchased one share of TPL on March 4, 2026 for $530.21. The firm now directly holds 3,469,108 shares. The transaction occurs as Texas Pacific Land reported Q4 2025 earnings and revenue that missed analyst expectations, and as KeyBanc increased its price ta…
Woodward, Inc. Chairman and CEO Charles P. Blankenship sold $3,845,466 of company shares on March 3 and March 4, 2026, under a Rule 10b5-1 plan adopted December 2, 2025, while also exercising options to acquire 10,000 shares. The trades were disclosed on a Form 4 filing. The transactions occur amid a strong first-quarter fiscal 2026 performance fro…
Shawn M. McLevige, Executive Vice President and President, Aerospace at Woodward, Inc. (WWD), sold 1,740 shares on March 3, 2026, for $711,088 and exercised options to acquire 1,850 shares the same day. The transactions occurred around the stock's trading price and follow a robust Q1 fiscal 2026 performance and an upgraded UBS price target.
David Foehr, Ceribell's senior vice president of finance and public affairs, sold 4,560 shares of Ceribell common stock on March 3, 2026 for $17.80 per share, totaling $81,168, and exercised options to acquire the same number of shares at $4.70 per share. The transactions were made under a Rule 10b5-1 plan adopted on September 4, 2025. Ceribell als…
Ceribell director Rebecca Robertson sold 827 shares of the company's common stock on March 3, 2026, under a Rule 10b5-1 plan for $17.80 per share, generating proceeds of $14,720. The sale leaves Robertson with 18,749 shares. The transaction occurs amid mixed signals for the company - short-term share weakness but strong six-month gains - while Ceri…
Ceribell President and CEO Chao Xingjuan sold 39,000 shares on March 3, 2026, for about $680,564 under a Rule 10b5-1 plan, while also exercising 25,000 options. The company received FDA Breakthrough Device designation for its LVO stroke detection monitor and saw BTIG reiterate a Buy rating with a $30 target.
